Bioventus expands hyaluronic acid product for osteoarthritis into Australia, New Zealand

Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand.

Advertisement

Four things to know:

1. Durolane is used in the symptomatic treatment of mild to moderate hip osteoarthritis and mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes.

2. The orthobiologic company is also launching another HA-based product, Durolane SJ, in both countries later this year.

3. Durolane SJ is used in the symptomatic treatment of mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes.

4. Both products are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the operation.

More articles on biologics:
Laser Spine Institute co-founders now owe ex-business partner $300M+, judge rules
Academic panel to define best practices for outpatient stem cell procedure
The big trends, issues in spine shaping practices today

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Biologics

  • Regenerative medicine company Auragens has opened an orthobiologics division.  Orthopedic surgeon Abdiel Ortiz, MD, will lead the new division, which…

  • So far this year, medtech companies and academic institutions are making key strides in spine biologics. From new product launches…

Advertisement

Comments are closed.